No Data
Progressive Hits 5-week Low
Express News | NYSE Order Imbalance 61666.0 Shares on Buy Side
Transposon Receives US FDA Fast Track Designation for TPN-101 for Progressive Supranuclear Palsy
Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative ...
Progressive Ranked 'Top Pick' by Morgan Stanley on Growth, Valuation
Progressive (PGR) has been ranked a "top pick" by Morgan Stanley, citing strong growth prospects and attractive pricing, while also noting that growth and margin remain "underappreciated". "The stock
Progressive Is Maintained at Overweight by Wells Fargo
Progressive Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains Overweight on Progressive, Lowers Price Target to $243
Wells Fargo analyst Elyse Greenspan maintains Progressive with a Overweight and lowers the price target from $244 to $243.